Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers.

BACKGROUND: The aim of this initial study was to evaluate the clinical and radiological effectiveness of radioembolization (RE) using 188Re-Human Serum Albumin (HSA) microspheres in patients with advanced, progressive, unresectable primary or secondary liver cancers, not suitable to any other form of therapy. MATERIAL/METHODS: Overall, we included 13 patients with 20 therapy sessions. Clinical and radiological responses were assessed at 6 weeks after therapy, and then every 3 months. The objective radiological response was classified according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.0 by sequential MRI. Adverse events were evaluated using NCI CTCAE v.4.03. RESULTS: There were 4 patients with hepatocellular carcinoma (HCC), 6 with metastatic colorectal cancer (mCRC), 2 with neuroendocrine carcinoma (NEC), and 1 patient with ovarian carcinoma. Mean administered activity of 188Re HSA was 7.24 GBq (range 3.8-12.4) A high microspheres labeling efficacy of over 97±2.1% and low urinary excretion of 188Re (6.5±2.3%) during first 48-h follow-up. Median overall survival (OS) for all patients was 7.1 months (CI 6.2-13.3) and progression-free survival (PFS) was 5.1 months (CI 2.4-9.9). In those patients who had a clinical partial response (PR), stable disease (SD), and disease progression (DP) as assessed 6 weeks after therapy, the median OS was 9/5/4 months, respectively, and PFS was 5/2/0 months, respectively. The treatment adverse events (toxicity) were at an acceptable level. Initially and after 6 weeks, the CTC AE was grade 2, while after 3 months it increased to grade 3 in 4 subjects. This effect was mostly related to rapid cancer progression in this patient subgroup. CONCLUSIONS: The results of this preliminary study indicate that RE using 188Re HSA is feasible and a viable option for palliative therapy in patients with extensive progressive liver cancer. It was well tolerated by most patients, with a low level of toxicity during the 3 months of follow-up.

Personalized image-based radiation dosimetry for routine clinical use in peptide receptor radionuclide therapy: pretherapy experience.

Patient-specific dose calculations are not routinely performed for targeted radionuclide therapy procedures, partly because they are time consuming and challenging to perform. However, it is becoming widely recognized that a personalized dosimetry approach can help plan treatment and improve understanding of the dose-response relationship. In this chapter, we review the procedures and essential elements of an accurate internal dose calculation and propose a simplified approach that is aimed to be practical for use in a busy nuclear medicine department.

177Lu SPECT imaging in the presence of90Y: does90Y degrade image quantification? a simulation study.

This work aims to investigate the accuracy of quantitative SPECT imaging of177Lu in the presence of90Y, which occurs in dual-isotope radiopharmaceutical therapy (RPT) involving both isotopes. We used the GATE Monte Carlo simulation toolkit to conduct a phantom study, simulating spheres filled with177Lu and90Y placed in a cylindrical water phantom that was also filled with activity of both radionuclides. We simulated multiple phantom configurations and activity combinations by varying the location of the spheres, the concentrations of177Lu and90Y in the spheres, and the amount of background activity. We investigated two different scatter window widths to be used with triple energy window (TEW) scatter correction. We also created multiple realizations of each configuration to improve our assessment, leading to a total of 540 simulations. Each configuration was imaged using a simulated Siemens SPECT camera. The projections were reconstructed using the standard 3D OSEM algorithm, and errors associated with177Lu activity quantification and contrast-to-noise ratios (CNRs) were determined. In all configurations, the quantification error was within ± 6% of the no-90Y case, and we found that quantitative accuracy may slightly improve when90Y is present because of reduction of errors associated with TEW scatter correction. The CNRs were not significantly impacted by the presence of90Y, but they were increased when a wider scatter window width was used for TEW scatter correction. The width of the scatter windows made a small but statistically significant difference of 1%-2% on the recovered177Lu activity. Based on these results, we can conclude that activity quantification of177Lu and lesion detectability is not degraded by the presence of90Y.

Preclinical PET Imaging and Toxicity Study of a 68Ga-Functionalized Polymeric Cardiac Blood Pool Agent.

Cardiac blood pool imaging is currently performed almost exclusively with 99mTc-based compounds and SPECT/CT imaging. Using a generator-based PET radioisotope has a few advantages, including not needing nuclear reactors to produce it, obtaining better resolution in humans, and potentially reducing the radiation dose to the patient. When the shortlived radioisotope 68Ga is used, it can be applied repeatedly on the same day-for example, for the detection of bleeding. Our objective was to prepare and evaluate a long-circulating polymer functionalized with gallium for its biodistribution, toxicity, and dosimetric properties. A 500 kDa hyperbranched polyglycerol was conjugated to the chelator NOTA and radiolabeled rapidly at room temperature with 68Ga. It was then injected intravenously into a rat, and gated imaging allowed us to easily observe wall motion and cardiac contractility, confirming the suitability of this radiopharmaceutical for cardiac blood pool imaging. Internal radiation dose calculations showed that the radiation doses that patients would receive from the PET agent would be 2.5× lower than those from the 99mTc agent. A complete 14-day toxicology study in rats concluded that there were no gross pathology findings, changes in body or organ weights, or histopathological events. This radioactive-metal-functionalized polymer might be a suitable non-toxic agent to advance for clinical application.

Toward a practical template-based approach to semiquantitative SPECT myocardial perfusion imaging.

PURPOSE: Our template-based quantitative perfusion single photon emission computed tomography (SPECT) method (T-QPS) performs semiquantitative analysis for myocardial perfusion imaging (MPI) without the use of normal databases. However, in its current form, T-QPS requires extensive calculations, which limits its clinical application. In the interest of clinical feasibility, the authors examine the trade-off between accuracy and processing time as the method is simplified. METHODS: The T-QPS method uses the reconstructed SPECT image of the patient to create a 3D digital template of his∕her healthy heart. This template is then projected, reconstructed, and sampled into the bulls-eye map domain. A ratio of the patient and template images produces a final corrected image in which a threshold is applied to identify perfusion defects. In principle, the template should be constructed with the heart and all extracardiac activity, and the projection step should include primary and scatter components; however, this leads to lengthy calculations. In an attempt to shorten the processing time, the authors analyzed the performance of four template (T) generation methods: T(P-HRT), T(PS-HRT), T(P-HRTBKG), and T(PS-HRTBKG), where P and S represent primary and scattered photons included in the projection step, respectively; and HRT and HRTBKG represent template constructed with the heart only and the heart with background activity, respectively. Forty-eight thorax phantoms and 21 randomly selected patient studies were analyzed using each approach. All studies used GE's Infinia Hawkeye SPECT∕CT system and followed a standard cardiac acquisition protocol. RESULTS: Approximate processing times for the T(P-HRT), T(PS-HRT), T(P-HRTBKG), and T(PS-HRTBKG) methods were less than a minute, 2-3 h, less than a minute and 3-4 h, respectively. In both the simulation and patient studies, a significant reduction in the quality of perfusion defect definition was exhibited by the T(P-HRT) method relative to the other three methods. The optimal method with respect to perfusion defect definition and processing time was T(P-HRTBKG) with a sensitivity, specificity, and accuracy in spatially defining the perfusion defects (simulation study) of 80%, 84%, and 83%, respectively. CONCLUSIONS: The T-QPS method using T(P-HRTBKG) leads to accurate and fast semiquantitative analysis of SPECT MPI, without the use of normal databases.

Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Theranostics is an emerging paradigm that combines imaging and therapy in order to personalize patient treatment. In nuclear medicine, this is achieved by using radiopharmaceuticals that target identical molecular targets for both imaging (using emitted gamma rays) and radiopharmaceutical therapy (using emitted beta, alpha or Auger-electron particles) for the treatment of various diseases, such as cancer. If the therapeutic radiopharmaceutical cannot be imaged quantitatively, a "theranostic pair" imaging surrogate can be used to predict the absorbed radiation doses from the therapeutic radiopharmaceutical. However, theranostic dosimetry assumes that the pharmacokinetics and biodistributions of both radiopharmaceuticals in the pair are identical or very similar, an assumption that still requires further validation for many theranostic pairs. In this review, we consider both same-element and different-element theranostic pairs and attempt to determine if factors exist which may cause inaccurate dose extrapolations in theranostic dosimetry, either intrinsic (e.g. chemical differences) or extrinsic (e.g. injecting different amounts of each radiopharmaceutical) to the radiopharmaceuticals. We discuss the basis behind theranostic dosimetry and present common theranostic pairs and their therapeutic applications in oncology. We investigate general factors that could create alterations in the behavior of the radiopharmaceuticals or the quantitative accuracy of imaging them. Finally, we attempt to determine if there is evidence showing some specific pairs as suitable for theranostic dosimetry. We show that there are a variety of intrinsic and extrinsic factors which can significantly alter the behavior among pairs of radiopharmaceuticals, even if they belong to the same chemical element. More research is needed to determine the impact of these factors on theranostic dosimetry estimates and on patient outcomes, and how to correctly account for them.

Fast image reconstruction for Compton camera using stochastic origin ensemble approach.

PURPOSE: Compton camera has been proposed as a potential imaging tool in astronomy, industry, homeland security, and medical diagnostics. Due to the inherent geometrical complexity of Compton camera data, image reconstruction of distributed sources can be ineffective and/or time-consuming when using standard techniques such as filtered backprojection or maximum likelihood-expectation maximization (ML-EM). In this article, the authors demonstrate a fast reconstruction of Compton camera data using a novel stochastic origin ensembles (SOE) approach based on Markov chains. METHODS: During image reconstruction, the origins of the measured events are randomly assigned to locations on conical surfaces, which are the Compton camera analogs of lines-of-responses in PET. Therefore, the image is defined as an ensemble of origin locations of all possible event origins. During the course of reconstruction, the origins of events are stochastically moved and the acceptance of the new event origin is determined by the predefined acceptance probability, which is proportional to the change in event density. For example, if the event density at the new location is higher than in the previous location, the new position is always accepted. After several iterations, the reconstructed distribution of origins converges to a quasistationary state which can be voxelized and displayed. RESULTS: Comparison with the list-mode ML-EM reveals that the postfiltered SOE algorithm has similar performance in terms of image quality while clearly outperforming ML-EM in relation to reconstruction time. CONCLUSIONS: In this study, the authors have implemented and tested a new image reconstruction algorithm for the Compton camera based on the stochastic origin ensembles with Markov chains. The algorithm uses list-mode data, is parallelizable, and can be used for any Compton camera geometry. SOE algorithm clearly outperforms list-mode ML-EM for simple Compton camera geometry in terms of reconstruction time. The difference in computational time will be much larger when full Compton camera system model, including resolution recovery, is implemented and realistic Compton camera geometries are used. It was also shown in this article that while correctly reconstructing the relative distribution of the activity in the object, the SOE algorithm tends to underestimate the intensity values and increase variance in the images; improvements to the SOE reconstruction algorithm will be considered in future work.

A template-based approach to semi-quantitative SPECT myocardial perfusion imaging: Independent of normal databases.

PURPOSE: Normal patient databases (NPDs) are used to distinguish between normal and abnormal perfusion in SPECT myocardial perfusion imaging (MPI) and have gained wide acceptance in the clinical environment, yet there are limitations to this approach. This study introduces a template-based method for semi-quantitative MPI, which attempts to overcome some of the NPD limitations. METHODS: Our approach involves the construction of a 3D digital healthy heart template from the delineation of the patient's left ventricle in the SPECT image. This patient-specific template of the heart, filled with uniform activity, is then analytically projected and reconstructed using the same algorithm as the original image. Subsequent to generating bulls-eye maps for the patient image (PB) and the template image (TB), a ratio (PB/TB) is calculated, which produces a reconstruction-artifact corrected image (CB). Finally, a threshold is used to define defects within CB enabling measurements of the perfusion defect extent (EXT). The SPECT-based template (Ts) measurements were compared to those of a CT-based "ideal" template (TI). Twenty digital phantoms were simulated: male and female, each with one healthy heart and nine hearts with various defects. Four physical phantom studies were performed modeling a healthy heart and three hearts with different defects. The phantom represented a thorax with spine, lung, and left ventricle inserts. Images were acquired on General Electric's (GE) Infinia Hawkeye SPECT/CT camera using standard clinical MPI protocol. Finally, our method was applied to 14 patient MPI rest/stress studies acquired on the GE Infinia Hawkeye SPECT/CT camera and compared to the results obtained from Cedars-Sinai's QPS software. RESULT: In the simulation studies, the true EXT correlated well with the TI (slope= 1.08; offset = -0.40%; r = 0.99) and Ts (slope = 0.90; offset = 0.27%; r = 0.99) methods with no significant differences between them. Similarly, strong correlations were measured for EXT obtained from QPS and the template method for patient studies (slope =0.91; offset = 0.45%; r = 0.98). Mean errors in extent for the Ts method using simulation, physical phantom, and patient data were 2.7% +/- 2.4%, 0.9% +/- 0.5%, 2.0% +/- 2.7%, respectively. CONCLUSIONS: The authors introduced a method for semi-quantitative SPECT MPI, which offers a patient-specific approach to define the perfusion defect regions within the heart, as opposed to the patient-averaged NPD methodology.

Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.

Because of challenges in performing routine personalized dosimetry in radiopharmaceutical therapies, interest in single-time-point (STP) dosimetry, particularly using only a single SPECT scan, is on the rise. Meanwhile, there are questions about the reliability of STP dosimetry, with limited independent validations. In the present work, we analyzed 2 STP dosimetry methods and evaluated dose errors for several radiopharmaceuticals based on effective half-life distributions. Methods: We first challenged the common assumption that radiopharmaceutical effective half-lives across the population are gaussian-distributed (i.e., follow a normal distribution). Then, dose accuracy was estimated using 2 STP dosimetry methods for a wide range of potential post injection (p.i.) scan time points for different radiopharmaceuticals applied to neuroendocrine tumors and prostate cancer. The accuracy and limitations of each of the STP methods were discussed. Results: A lognormal distribution was more appropriate for capturing effective half-life distributions. The STP framework was promising for dosimetry of 177Lu-DOTATATE and for kidney dosimetry of different radiopharmaceuticals (errors < 30%). Meanwhile, for some radiopharmaceuticals, STP accuracy was compromised (e.g., in bone marrow and tumors for 177-labeled prostate-specific membrane antigen [PSMA])). The optimal SPECT scanning time for 177Lu-DOTATATE was approximately 72 h p.i., whereas 48 h p.i. was better for 177Lu-PSMA. Conclusion: Simplified STP dosimetry methods may compromise the accuracy of dose estimates, with some exceptions, such as for 177Lu-DOTATATE and for kidney dosimetry in different radiopharmaceuticals. Simplified personalized dosimetry in the clinic continues to be challenging. On the basis of our results, we make suggestions and recommendations for improved personalized dosimetry using simplified imaging schemes.

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T.

BACKGROUND: Patients with metastatic, castration-resistant prostate cancer (mCRPC) present with an increased tumor burden in the skeleton. For these patients, Lutetium-177 (Lu-177) radioligand therapy targeting the prostate-specific membrane antigen (PSMA) has gained increasing interest with promising outcome data. Patient-individualized dosimetry enables improvement of therapy success with the aim of minimizing absorbed dose to organs at risk while maximizing absorbed dose to tumors. Different dosimetric approaches with varying complexity and accuracy exist for this purpose. The Medical Internal Radiation Dose (MIRD) formalism applied to tumors assumes a homogeneous activity distribution in a sphere with unit density for derivation of tumor S values (TSV). Voxel S value (VSV) approaches can account for heterogeneous activities but are simulated for a specific tissue. Full patient-individual Monte Carlo (MC) absorbed dose simulation addresses both, heterogeneous activity and density distributions. Subsequent CT-based density weighting has the potential to overcome the assumption of homogeneous density in the MIRD formalism with TSV and VSV methods, which could be a major limitation for the application in bone metastases with heterogeneous density. The aim of this investigation is a comparison of these methods for bone lesion dosimetry in mCRPC patients receiving Lu-177-PSMA therapy. RESULTS: In total, 289 bone lesions in 15 mCRPC patients were analyzed. Percentage difference (PD) of average absorbed dose per lesion compared to MC, averaged over all lesions, was + 14 ± 10% (min: - 21%; max: + 56%) for TSVs. With lesion-individual density weighting using Hounsfield Unit (HU)-to-density conversion on the patient's CT image, PD was reduced to - 8 ± 1% (min: - 10%; max: - 3%). PD on a voxel level for three-dimensional (3D) voxel-wise dosimetry methods, averaged per lesion, revealed large PDs of + 18 ± 11% (min: - 27%; max: + 58%) for a soft tissue VSV approach compared to MC; after voxel-wise density correction, this was reduced to - 5 ± 1% (min: - 12%; max: - 2%). CONCLUSION: Patient-individual MC absorbed dose simulation is capable to account for heterogeneous densities in bone lesions. Since the computational effort prevents its routine clinical application, TSV or VSV dosimetry approaches are used. This study showed the necessity of lesion-individual density weighting for TSV or VSV in Lu-177-PSMA therapy bone lesion dosimetry.

An investigation of potential sources of artifacts in SPECT-CT myocardial perfusion studies.

BACKGROUND: The increased use of hybrid SPECT-CT systems in myocardial perfusion imaging calls for a careful review of protocols that are employed in data acquisition and processing. Our study investigates the cases of potential false perfusion defects that may appear in cardiac images reconstructed with CT-based attenuation correction and high-resolution acquisition matrix. METHODS: Phantom experiments performed on Infinia-Hawkeye (GE Healthcare) modeling patients with normal hearts and different body sizes and shapes were reconstructed using standard ordered subsets expectation maximization (OSEM) method with 10 subsets and 2-50 iterations. The CT-based attenuation correction (AC) with and without distance-dependent resolution recovery (RR) were employed. RESULTS: Images reconstructed from scans with a standard thorax phantom did not show any artifacts. However, some images reconstructed from the data with extra water bags (modeling high and non-uniformly distributed attenuation) clearly displayed false perfusion defects. A potential for creating such artifacts was especially high in complex reconstruction cases. In most cases, the severity of defects decreased when reconstructions with more iterations were used. CONCLUSIONS: In situations with strong and non-uniform attenuation, the reconstruction methods with sophisticated data processing (large matrix size, AC + RR corrections) may require substantially more processing than is currently used and/or recommended.

Dual-isotope acquisition for CT-SPECT registration of infection studies.

The registration of CT and NM images can enhance patient diagnosis since it allows for the fusion of anatomical and functional information as well as attenuation correction of NM images. However, irrespective of the methods used, registration accuracy depends heavily on the characteristics of the input images and the degree of similarity between them. This poses a challenge for registering CT and NM images as they may have very different characteristics. To address the particular problem of CT and In-111 SPECT registration, we propose to perform a dual-isotope study which involves an additional injection of Tc-99m MDP to generate two inherently registered images: In-111 SPECT and Tc-99m SPECT. As skeletal structures are visible in both CT and Tc-99m SPECT, performing registration of these images may be much more effective. The very same spatial transformation derived can be immediately applied to complete the registration of CT and the corresponding In-111 SPECT. Accordingly, we hypothesize that the registration of CT and Tc-99m SPECT can be more accurately performed than the registration of CT and In-111 SPECT and seek to compare the accuracies between the aforementioned registrations. In this paper, we have collected three clinical datasets, with the ground-truth transformations known, and tested the proposed approach by using a mutual information-based algorithm to solve for the rigid/non-rigid misalignments introduced to them. Based on the results of our experiments, we conclude that registration using Tc-99m SPECT can achieve 100% success rate, and is thus much more superior to the registration using In-111 SPECT, which at best, achieves only 38% success rate. Clearly, the introduction of a dual-isotope acquisition can substantially improve the registration of SPECT and CT images.

Impact of image reconstruction method on dose distributions derived from 90Y PET images: phantom and liver radioembolization patient studies.

PET images acquired after liver 90Y radioembolization therapies are typically very noisy, which significantly challenges both visualization and quantification of activity distributions. To improve their noise characteristics, regularized iterative reconstruction algorithms such as block sequential regularized expectation maximization (Q.Clear for GE Healthcare, USA) have been proposed. In this study, we aimed to investigate the effects which different reconstruction algorithms may have on patient images, with reconstruction parameters initially narrowed down using phantom studies. Moreover, we evaluated the impact of these reconstruction methods on voxel-based dose distribution in phantom and patient studies (lesions and healthy livers). The International Electrotechnical Commission (IEC)/NEMA phantom, containing six spheres, was filled with 90Y and imaged using a GE Discovery 690 PET/CT scanner with time-of-flight enabled. The images were reconstructed using Q.Clear (with ß parameter ranging from 0 to 8000) and ordered subsets expectation maximization. The image quality and quantification accuracy were evaluated by computing the hot ([Formula: see text]) and cold ([Formula: see text]) contrast recovery coefficients, background variability (BV) and activity bias. Next, dose distributions and dose volume histograms were generated using MIM® software's SurePlan LiverY90 toolbox. Subsequently, parameters optimized in these phantom studies were applied to five patient datasets. Dose parameters, such as Dmax, Dmean, D70, and V100Gy, were estimated, and their variability for different reconstruction methods was investigated. Based on phantom studies, the ß parameter values optimized for image quality and quantification accuracy were 2500 and 300, respectively. When all investigated reconstructions were applied to patient studies, Dmean, D50, D70, and V100Gy showed coefficients of variation below 8%; whereas the variability of Dmax was up to 30% for both phantom and patient images. Although ß = 300-1000 would provide accurate activity quantification for a region of interest, when considering activity/dose voxelized distribution, higher ß value (e.g. 4000-5000) would provide the greatest accuracy for dose distributions. In this 90Y radioembolization PET/CT study, the ß parameter in regularized iterative (Q.Clear) reconstruction was investigated for image quality, accurate quantification and dose distributions based on phantom experiments and then applied to patient studies. Our results indicate that more accurate dose distribution can be achieved from smoother PET images, reconstructed with larger ß values than those yielding the best activity quantifications but noisy images. Most importantly, these results suggest that quantitative measures, which are commonly used in clinics, such as SUVmax or SUVpeak( equivalent of Dmax), should not be employed for 90Y PET images, since their values would highly depend on the image reconstruction.

Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction.

BACKGROUND: Personalization of 177Lu-based radionuclide therapy requires implementation of dosimetry methods that are both accurate and practical enough for routine clinical use. Quantitative single-photon emission computed tomography/computed tomography (QSPECT/CT) is the preferred scanning modality to achieve this and necessitates characterizing the response of the camera, and calibrating it, over the full range of therapeutic activities and system capacity. Various methods to determine the camera calibration factor (CF) and the deadtime constant (τ) were investigated, with the aim to design a simple and robust protocol for quantitative 177Lu imaging. METHODS: The SPECT/CT camera was equipped with a medium energy collimator. Multiple phantoms were used to reproduce various attenuation conditions: rod sources in air or water-equivalent media, as well as a Jaszczak phantom with inserts. Planar and tomographic images of a wide range of activities were acquired, with multiple energy windows for scatter correction (double or triple energy window technique) as well as count rate monitoring over a large spectrum of energy. Dead time was modelled using the paralysable model. CF and τ were deduced by curve fitting either separately in two steps (CF determined first using a subset of low-activity acquisitions, then τ determined using the full range of activity) or at once (both CF and τ determined using the full range of activity). Total or segmented activity in the SPECT field of view was computed. Finally, these methods were compared in terms of accuracy to recover the known activity, in particular when planar-derived parameters were applied to the SPECT data. RESULTS: The SPECT camera was shown to operate as expected on a finite count rate range (up to ~ 350 kcps over the entire energy spectrum). CF and τ from planar (sources in air) and SPECT segmented Jaszczak data yielded a very good agreement (CF < 1% and τ < 3%). Determining CF and τ from a single curve fit made dead-time-corrected images less prone to overestimating recovered activity. Using triple-energy window scatter correction while acquiring one or more additional energy window(s) to enable wide-spectrum count rate monitoring (i.e. ranging 55-250 or 18-680 keV) yielded the most consistent results across the various geometries. The final, planar-derived calibration parameters for our system were a CF of 9.36 ± 0.01 cps/MBq and a τ of 0.550 ± 0.003 µs. Using the latter, the activity in a Jaszczak phantom could be quantified by QSPECT with an accuracy of 0.02 ± 1.10%. CONCLUSIONS: Serial planar acquisitions of sources in air using an activity range covering the full operational capacity of the SPECT/CT system, with multiple energy windows for wide-spectrum count rate monitoring, and followed by simultaneous determination of CF and τ using a single equation derived from the paralysable model, constitutes a practical method to enable accurate dead-time-corrected QSPECT imaging in a post-177Lu radionuclide therapy setting.

A multi-center phantom study comparing image resolution from three state-of-the-art SPECT-CT systems.

BACKGROUND: Ongoing advancements in SPECT-CT technology raise important questions regarding the differences in performance between various cameras and their respective image-processing algorithms. Our study seeks the answer to this question via measurement of phantom myocardial wall thickness (MWT) on images obtained from three state-of-the-art cameras. METHODS: A thorax phantom with an insert modeling a healthy heart was scanned using cardiac acquisition protocols with Philips' Precedence (PP), GE's Infinia Hawkeye (IH), and Siemens' Symbia-T6 (SS). Processing was performed using advanced reconstruction techniques available on the cameras and our own independent software. The MWT measurement was used as a figure of merit in performance evaluation. RESULTS: When using 50% threshold, MWTs measured for the data acquired using PP, IH, and SS and reconstructed with independent standardized software were 8.5 +/- 1.2 mm, 7.7 +/- 1.2 mm, and 9.3 +/- 0.9 mm, respectively; and 9.3 +/- 0.5 mm, 19.2 +/- 0.8 mm and 18.4 +/- 1.1 mm when using the manufacturers' own reconstructions, respectively. Thresholds optimized for each image (ranging from 32% to 68%) produced much more uniform results. CONCLUSIONS: No significant differences were observed between image resolutions when data acquired from different cameras were reconstructed with an independent algorithm. However, different manufacturers' reconstruction algorithms produced MWTs that differed by up to about 110% when using a set threshold of 50%.

Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations.

Peptide receptor radionuclide therapy (PRRT) with 177Lu- radiolabeled octreotate is an effective treatment method for inoperable neuroendocrine tumours (NETs). There is growing evidence that estimates of the organ-at-risks (OARs) doses are necessary for the optimization of personalized PRRT (P-PRRT). Dosimetry, however, requires a complicated and time-consuming procedure, which hinders its implementation in the clinic. The aim of this study is to develop a practical and automatic technique to simplify personalized dosimetry of kidney, the major OAR in 177Lu P-PRRT. The data from 30 NETs patients undergoing 44 personalized 177Lu-DOTA-TATE therapy cycles were analyzed. To determine the biokinetics of the radiopharmaceutical in the kidneys, for each patient three SPECT/CT scans were acquired, at about 4 h, 24 h and 70 h after injection. The kidneys doses were evaluated using three different approaches: (1) a traditional approach based on whole kidney (WK) segmentation; (2) a small volume (SV) manual approach (M-SV) with observer-defined SV location; and (3) a software based SV-approach that automatically defines SV location (A-SV). Four different methods of automatic SV location selections were investigated. The SV kidney doses estimated using M-SV and A-SV approaches was evaluated and the accuracy of these two approaches were compared to the WK dosimetry. The kidney bio-kinetics, in terms of effective half-lives, obtained from both of the A-SV and M-SV approaches agreed to within 10% with those obtained from the WK segmentation. The average ratios of SV doses to WK doses were mostly about 1.8 ± 0.2 for both A-SV and M-SV approaches. The linear correlation coefficients between SV doses (both A-SV and M-SV) and WK doses were up to 0.9 with p  < 0.001. The differences between A-SV and M-SV were minor. By comparing different methods of SV location selections, independently selecting SV in images from each of the acquisitions was proved the most appropriate and accurate approach. An automatic, observer-independent method for selecting the location of the small volume in kidneys was developed. The accuracy of this dose estimation approach has been demonstrated by comparing it with the manual SV dosimetry, as well as the WK dosimetry. The proposed automatic approach can potentially be considered as a practical and simple method for dose estimation in the future clinical studies.

Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study.

177Lu-DOTATATE therapy has been shown to produce encouraging results in treatment of neuroendocrine tumours (NETs). Unfortunately, since dosimetry for radionuclide therapy is considered to be challenging, typically similar amount of radiopharmaceutical is administered to every patient. There is growing evidence that the efficacy of this therapy can be significantly improved by employing personalized protocols, based on the organ-at-risk dosimetry. The aim of this study is to propose a practical and accurate dosimetry protocol based on the simplified acquisition schedules. Data from fifty-three therapy cycles in thirty-nine NET patients were analyzed. Three SPECT/CT scans, acquired at 4 h (D0), 23 h (D1) and 70 h (D3) after injection, were performed. The kidney volume was determined using CT and the activity was determined from quantitative SPECT using an iterative thresholding method. For each dataset, four methods were used to model the time-activity-curves (TAC): M1-two trapezoid segments (0 to D0 and D0 to D1), followed by monoexponential fit to D1 + D3 data; M2-monoexponential fit to D0 + D1 + D3 data; M3 and M4-monoexponential fit to D0 + D3 and D1 + D3 data, respectively. Additionally, kidney doses obtained from single time point method using a monoexponential curve with the population mean effective half-life, normalized to activities at D0 or D1 or D3 points, were calculated. The accuracy of simplified dosimetry methods was assessed as the percentage difference relative to doses calculated from M1. The major contribution to the absorbed dose estimate comes from the area under the late time portion of the TAC (D1 to infinity). Therefore, information from the late scan (D3) is crucial for the determination of kidney absorbed doses. Single time point method using monoexponential TAC, with the population mean effective half-life normalized to the late data point (48-72 h for kidneys) produces <10% deviation in the absorbed dose estimation, thus is recommended for clinical use.

Validation of mutual information-based registration of CT and bone SPECT images in dual-isotope studies.

The registration of computed tomography (CT) and nuclear medicine (NM) images can substantially enhance patient diagnosis as it allows for the fusion of anatomical and functional information, as well as the attenuation correction of NM images. However, irrespective of the method used, registration accuracy depends heavily on the characteristics of the images that are registered and the degree of similarity between them. This poses a challenge for registering CT and NM images as they have very different characteristics and content. To address the particular problem of registering single photon emission computed tomography (SPECT) oncology studies with corresponding CT, we have proposed to perform a dual-isotope study with simultaneous injection of a tumor tracer and a bone imaging agent to obtain a tumor SPECT and a bone SPECT image that are inherently registered. As bone structures are generally visible in both CT and bone SPECT, performing registration of these images will be more easily attainable than registration of CT and tumor SPECT. By subsequently applying the spatial transformation determined from this registration to the tumor SPECT acquired from the same dual-isotope study, the optimal alignment between the CT and tumor SPECT images can be obtained. In this paper, we present the proof-of-concept of the proposed approach, the MI-based algorithm employed, and the techniques used to select the algorithm's parameters. Our objectives are to show the feasibility of CT and bone SPECT registration using this algorithm and to validate quantitatively the results generated using clinical data.

Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans.

BACKGROUND: Rhenium-188-labelled-Lipiodol radioembolization is a safe and cost-effective treatment for primary liver cancer. In order to determine correlations between treatment doses and patient response to therapy, accurate patient-specific dosimetry is required. Up to date, the reported dosimetry of 188Re-Lipiodol has been based on whole-body (WB) planar imaging only, which has limited quantitative accuracy. The aim of the present study is to determine the in vivo pharmacokinetics, bio-distribution, and organ-level dosimetry of 188Re-AHDD-Lipiodol radioembolization using a combination of post-treatment planar and quantitative SPECT/CT images. Furthermore, based on the analysis of the pharmacokinetic data, a practical and relatively simple imaging and dosimetry method that could be implemented in clinics for 188Re-AHDD-Lipiodol radioembolization is proposed. Thirteen patients with histologically proven hepatocellular carcinoma underwent 188Re-AHDD-Lipiodol radioembolization. A series of 2-3 WB planar images and one SPECT/CT scan were acquired over 48 h after the treatment. The time-integrated activity coefficients (TIACs, also known as residence-times) and absorbed doses of tumors and organs at risk (OARs) were determined using a hybrid WB/SPECT imaging method. RESULTS: Whole-body imaging showed that 188Re-AHDD-Lipiodol accumulated mostly in the tumor and liver tissue but a non-negligible amount of the pharmaceutical was also observed in the stomach, lungs, salivary glands, spleen, kidneys, and urinary bladder. On average, the measured effective half-life of 188Re-AHDD-Lipiodol was 12.5 ± 1.9 h in tumor. The effective half-life in the liver and lungs (the two organs at risk) was 12.6 ± 1.7 h and 12.0 ± 1.9 h, respectively. The presence of 188Re in other organs was probably due to the chemical separation and subsequent release of the free radionuclide from Lipiodol. The average doses per injected activity in the tumor, liver, and lungs were 23.5 ± 40.8 mGy/MBq, 2.12 ± 1.78 mGy/MBq, and 0.11 ± 0.05 mGy/MBq, respectively. The proposed imaging and dosimetry method, consisting of a single SPECT/CT for activity determination followed by 188Re-AHDD-Lipiodol clearance with the liver effective half-life of 12.6 h, resulted in TIACs estimates (and hence, doses) mostly within ± 20% from the reference TIACs (estimated using three WB images and one SPECT/CT). CONCLUSIONS: The large inter-patient variability of the absorbed doses in tumors and normal tissue in 188Re-HDD-Lipiodol radioembolization patients emphasizes the importance of patient-specific dosimetry calculations based on quantitative post-treatment SPECT/CT imaging.

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT.

BACKGROUND: Routine dosimetry is essential for personalized 177Lu-octreotate peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs), but practical and robust dosimetry methods are needed for wide clinical adoption. The aim of this study was to assess the accuracy and inter-observer reproducibility of simplified dosimetry protocols based on quantitative single-photon emission computed tomography (QSPECT) with a limited number of scanning time points. We also updated our personalized injected activity (IA) prescription scheme. METHODS: Seventy-nine NET patients receiving 177Lu-octreotate therapy (with a total of 279 therapy cycles) were included in our study. Three-time-point (3TP; days 0, 1, and 3) QSPECT scanning was performed following each therapy administration. Dosimetry was obtained using small volumes of interest activity concentration sampling for the kidney, the bone marrow and the tumor having the most intense uptake. Accuracy of the simplified dosimetry based on two-time-point (2TP; days 1 and 3, monoexponential fit) or a single-time-point (1TPD3; day 3) scanning was assessed, as well as that of hybrid methods based on 2TP for the first cycle and 1TP (day 1 or 3; 2TP/1TPD1 and 2TP/1TPD3, respectively) or no imaging at all (based on IA only; 2TP/no imaging (NI)) for the subsequent induction cycles. The inter-observer agreement was evaluated for the 3TP, 2TP, and hybrid 2TP/1TPD3 methods using a subset of 60 induction cycles (15 patients). The estimated glomerular filtration rate (eGFR), body size descriptors (weight, body surface area (BSA), lean body weight (LBW)), and products of both were assessed for their ability to predict IA per renal absorbed dose at the first cycle. RESULTS: The 2TP dosimetry estimates correlated highly with those from the 3TP data for all tissues (Spearman r > 0.99, P < 0.0001) with small relative errors between the methods, particularly for the kidney and the tumor, with median relative errors not exceeding 2% and interdecile ranges spanning over less than 6% and 4%, respectively, for the per-cycle and cumulative estimates. For the bone marrow, the errors were slightly greater (median errors < 6%, interdecile ranges < 14%). Overall, the strength of correlations of the absorbed dose estimates from the simplified methods with those from the 3TP scans tended to progressively decrease, and the relative errors to increase, in the following order: 2TP, 2TP/1TPD3, 1TPD3, 2TP/1TPD1, and 2TP/NI. For the tumor, the 2TP/NI scenario was highly inaccurate due to the interference of the therapeutic response. There was an excellent inter-observer agreement between the three observers, in particular for the renal absorbed dose estimated using the 3TP and 2TP methods, with mean errors lesser than 1% and standard deviations of 5% or lower. The eGFR · LBW and eGFR · BSA products best predicted the ratio of IA to the renal dose (GBq/Gy) for the first cycle (Spearman r = 0.41 and 0.39, respectively; P < 0.001). For the first cycle, the personalized IA proportional to eGFR · LBW or eGFR · BSA decreased the range of delivered renal absorbed dose between patients as compared with the fixed IA. For the subsequent cycles, the optimal personalized IA could be determined based on the prior cycle renal GBq/Gy with an error of less than 21% in 90% of patients. CONCLUSIONS: A simplified dosimetry protocol based on two-time-point QSPECT scanning on days 1 and 3 post-PRRT provides reproducible and more accurate dose estimates than the techniques relying on a single time point for non-initial or all cycles and results in limited patient inconvenience as compared to protocols involving scanning at later time points. Renal absorbed dose over the 4-cycle induction PRRT course can be standardized by personalizing IA based on the product of eGFR with LBW or BSA for the first cycle and on prior renal dosimetry for the subsequent cycles.